Want to see ROIV full AI Analyst Report?
ROIV Stock Chart & Stats
$36.47
-$0.09(-0.26%)
At close: 4:00 PM EDT
$36.47
-$0.09(-0.26%)
Day’s Range― - ―
52-Week Range$12.28 - $37.97
Previous CloseN/A
Volume4.04M
Average Volume (3M)6.64M
Market Cap
$25.02B
Enterprise Value$22.46K
Total Cash (Recent Filing)$3.84B
Total Debt (Recent Filing)$107.15M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Nov 16, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding722,323,000
10 Day Avg. Volume8,955,200
30 Day Avg. Volume6,639,825
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)4.25
Price to Sales (P/S)2326.88
P/FCF Ratio-25.34
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$42.44Price Target Upside16.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.35
Revenue Forecast (FY)$54.08M
Bulls Say, Bears Say
Bulls Say
FDA Approval Creates A Commercial AnchorLISRAYA provides Roivant with an approved commercial product, differentiated positioning in an underserved rare disease, and immediate launch capability. Its steroid-sparing benefits and specialty support infrastructure may help establish durable adoption.
Broad Pipeline Supports Multiple Future CatalystsMultiple clinical programs diversify Roivant’s development base beyond one asset and create several opportunities for future approvals, partnerships or commercial expansion. This pipeline breadth can support longer-term growth if execution and trial outcomes remain favorable.
Strong Balance Sheet Provides Funding FlexibilityVery low leverage and substantial equity give Roivant capacity to fund clinical development, commercialization and potential business development without immediate reliance on debt markets. The balance sheet also provides resilience against trial delays or uneven product launches.
Bears Say
Persistent Losses And Substantial Cash ConsumptionRoivant continues to convert operations into significant cash outflows, while net losses remain substantial. Sustained investment is necessary for pipeline development, but prolonged burn could reduce financial flexibility and increase dependence on future product success or portfolio transactions.
Declining Revenue Limits Current Commercial VisibilityThe current revenue base is not yet demonstrating durable scale, and operating costs continue to exceed gross profit despite strong gross margins. This leaves earnings quality and predictability weak until newly approved or partnered products contribute materially.
Clinical, Regulatory And JAK Uptake Risks Remain MaterialSeveral pipeline programs face endpoint, statistical or biological uncertainty, which could delay approvals or reduce expected value. In addition, boxed warnings and historical safety concerns around JAK inhibitors may constrain physician and payer uptake even after regulatory approval.
Roivant Sciences News
ROIV FAQ
What was Roivant Sciences’s price range in the past 12 months?
Roivant Sciences lowest stock price was $12.28 and its highest was $37.97 in the past 12 months.
What is Roivant Sciences’s market cap?
Roivant Sciences’s market cap is $25.02B.
When is Roivant Sciences’s upcoming earnings report date?
Roivant Sciences’s upcoming earnings report date is Nov 16, 2026 which is in 74 days.
How were Roivant Sciences’s earnings last quarter?
Roivant Sciences released its earnings results on Aug 06, 2026. The company reported -$0.335 earnings per share for the quarter, missing the consensus estimate of -$0.3 by -$0.035.
Is Roivant Sciences overvalued?
According to Wall Street analysts Roivant Sciences’s price is currently Undervalued.
Does Roivant Sciences pay dividends?
Roivant Sciences does not currently pay dividends.
What is Roivant Sciences’s EPS estimate?
Roivant Sciences’s EPS estimate is -0.36.
How many shares outstanding does Roivant Sciences have?
Roivant Sciences has 722,323,000 shares outstanding.
What happened to Roivant Sciences’s price movement after its last earnings report?
Roivant Sciences reported an EPS of -$0.335 in its last earnings report, missing expectations of -$0.3. Following the earnings report the stock price went up 1.503%.
Which hedge fund is a major shareholder of Roivant Sciences?
Currently, no hedge funds are holding shares in ROIV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Roivant Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.44 (16.36% Upside)
$42.44 (16.36% Upside)
Blogger Sentiment
Neutral
ROIV Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 5.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $240.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 8.0%
Last 30 Days ▲ 8.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
189.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.44%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Roivant Sciences
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
ROIV Company Deck
ROIV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong pipeline progress (potential DM launch, Phase III initiation in cutaneous sarcoidosis, multiple H2 2026 readouts), a sizable settlement cash inflow, active share buybacks, and continued R&D investment. Management was candid about clinical and regulatory risks (placebo variability, translation risk for PH‑ILD, randomized withdrawal uncertainty in D2T RA), limited early commercial visibility, JAK class safety perceptions, and contingent litigation outcomes. On balance, the positives (multiple near-term catalysts, strengthened balance sheet, active capital return, and robust R&D investment) outweigh the enumerated risks, which are largely development and execution uncertainties the company is actively managing.View all ROIV earnings summariesROIV Stock 12 Month Forecast
Average Price Target
$42.44
▲(16.36% Upside)
Technical Analysis
Ownership Overview
19.51% Insiders
16.93% Mutual Funds
22.14% Other Institutional Investors
27.04% Public Companies and
Individual Investors